Ollier disease

Last updated
Ollier disease
Ollier radio2.jpg
X-ray image showing enchondromas localized in the lower part of the radius of a 7-year-old girl with Ollier disease.
Specialty Medical genetics   OOjs UI icon edit-ltr-progressive.svg

Ollier disease is a rare sporadic nonhereditary skeletal disorder in which typically benign cartilaginous tumors (enchondromas) develop near the growth plate cartilage. This is caused by cartilage rests that grow and reside within the metaphysis or diaphysis and eventually mineralize over time to form multiple enchondromas. [1] Key signs of the disorder include asymmetry and shortening of the limb as well as an increased thickness of the bone margin. These symptoms are typically first visible during early childhood with the mean age of diagnosis being 13 years of age. [2] Many patients with Ollier disease are prone to develop other malignancies including bone sarcomas that necessitate treatment and the removal of malignant bone neoplasm. Cases in patients with Ollier disease has shown a link to IDH1, IDH2, and PTH1R gene mutations. Currently, there are no forms of treatment for the underlying condition of Ollier disease but complications such as fractures, deformities, malignancies that arise from it can be treated through surgical procedures. The prevalence of this condition is estimated at around 1 in 100,000. [3] It is unclear whether the men or women are more affected by this disorder due to conflicting case studies.

Contents

Presentation

The disease consists of the growth multiple enchondromas which usually develop in early childhood. The growth of these enchondromas usually stops after skeletal maturation. [4] The affected extremity is shortened (asymmetric dwarfism) and sometimes bowed due to epiphyseal fusion anomalies. Bone lesions generally present as cellular during childhood and become more solitary over time. People with Ollier disease are prone to breaking bones (fractures) and normally have swollen, aching limbs. However, many cases of solitary enchondromata go unnoticed due to lack of symptoms. Enchondromas are commonly found in the phalanges, metacarpal, and metatarsal bones in patients of Ollier disease due to the affinity of enchondromas to long tubular bones such as the femur and humerus. A unilateral distribution of bone lesions is usually observed but bilateral distributions or a singular extremity can occur as well. Approximately a third of the cases show some form of physical deformities of bowing or abnormal limb lengthening.[ citation needed ]

Associated conditions

Ollier disease carries a higher risk of malignancies such as central nervous system (CNS), ovarian, and adenocarcinoma. [5] Cranial gliomas have been linked with this disorder at an increased rate and at an earlier diagnosis age. [6] [7] [8] A majority of glioma cases contain IDH gene mutations thus explaining the link between the two conditions. Juvenile granulosa cell tumour has also been associated with the disease. [9] One case study indicates that this is due a mesodermal dysplasia in the long bones resulting in ovarian cancer. [10]

The incidence of a secondary chondrosarcoma in Ollier disease is most commonly approximated at 25–30% with some projections even as high as 50%. [11] [12] [13] Chondrosarcomas are typically developed during young adulthood and mostly form as a unifocal distribution in Ollier disease patients. [3] The most common locations of tumors are in the pelvis and shoulder girdle. [14] While chondrosarcoma is the most common form of a secondary malignant bone neoplasm found in cases of Ollier disease, other forms such as chordomas and osteosarcomas can occur. If left untreated, these malignant transformations may lead to fatal outcomes.[ citation needed ]

A related and even rarer disorder named Maffucci syndrome is a very similar condition that is characterized by the presence of multiple enchondromas with hemangiomas and occasionally lymphangiomas usually near the hands and feet but not limited to the skull, ribs, and spinal bones. [2] This disorder is also sporadic and nonhereditary and usually detected during childhood despite being a congenital condition. Maffucci syndrome has also similarly been linked to IDH1 and IDH2 mutations specifically the IDH1 R132C hotspot mutation. [15] This hotspot mutation is presumed to be responsible for the spindle cell hemangiomas and enchondromas in cases of Maffucci syndrome. Sanger sequencing analysis concluded that exon 4 is the primary location of mutations in IDH1 and IDH2 genes are specifically responsible for hemangiomas. Maffucci syndrome carries a significantly higher risk of malignant transformations like chondrosarcomas but also much more aggressive tumors such as acute lymphocytic leukemia and gastrointestinal and ovarian malignancies. [1] [16]

Cause

For many years, most research has been inconclusive regarding the cause of the disease. [1] [17]

Recent studies have shown that most cases of Ollier disease are believed to have been caused by isocitrate dehydrogenases IDH1 and IDH2 mutations. [18] In one study, 35 of 43 (81%) patients with Ollier disease had either a IDH1 or IDH2 mutation. [19] Another study suggests that R132C IDH1 mutations which are particularly dominant at exon 4 of IDH genes are linked to the growth of vascular lesions. [15] Isocitrate deyhydrogenases IDH1 and IDH2 are catalysts responsible for the conversion of isocitrate to 2-oxoglutarate. The isocitrate deyhydrogenases IDH1 and IDH2 mutations disrupt this process resulting in unregulated production of α-ketoglutarate and a reduction in chondrocyte proliferation. In many cases of cartilaginous tumors, IDH1 and IDH2 point mutations were found thus explaining why Ollier disease is associated with many different associated conditions. Based on these case studies, most evidence suggests that the abnormal lining of lesions found in Ollier disease would suggest that the condition is caused by a post-zygotic somatic mutation thus resulting in a mosaic genetic disorder. [20]

Approximately 8–10% of cases of patients with Ollier disease have been linked to PTH1R mutations. [17] [19] A particular case study the mutant heterozygous PTHR1 (R150C) receptor was observed in two unrelated patients with Ollier disease. [21] [22] This PTHR1 (R150C) mutant causes a reduction in chondrocyte differentiation by triggering the PTHrP-dependent pathway and decreasing PTHLH receptor function by approximately 30% creating enchondromas. One of these patients with the PTHR1 (R150C) mutant was found to have inherited the mutation from his father. This provides credence to the theory that multiple genetic mutations are needed to occur in order for Ollier disease to manifest.

An alternative theory suggests that since there have been cases of multiple family members with enchondromatosis, the disorder may be passed on through autosomal dominant inheritance. [1]

Diagnosis

Clinical and radiological evaluations are conducted in order to detect the presence of bone neoplasms or lesions typically found in Ollier disease. Histological evaluations are mainly used to examine or detect malignancies.

Abnormal bone growth such as shortening or thickening and deformity may be observed in patients of Ollier disease. These bone lesions are visible at birth using radiography but are usually not screened or examined for until clinical manifestations present during early childhood. However, some patients may exhibit no signs of any symptoms. [1] One study found thirteen to be the mean age of diagnosis in patients with Ollier disease. In an X-ray, there would normally be the presence of several homogeneous lesions of an oval or elongated shape with bone edges that are slightly thickened. [3] With age, these lesions may calcify and appear as diffusely minute spots or stippled. Fan-like septations or streaks would be indicative of the presence of several enchondromas. Early detection and consistent and repeated monitoring is important in order to prevent and treat any potential bone neoplasms.[ citation needed ]

Magnetic resonance imaging (MRI), ultrasound, and scintigraphy are generally not practical for diagnostic purposes. X-rays are not as effective in the monitoring or evaluation of enchondromas due to frequent localized changes also sometimes due to the large number of enchondromas. MRI can sometimes however be used to monitor and evaluate symptomatic lesions in the case of potential malignant transformations.

Similar disorders such as Maffucci syndrome and hereditary multiple exostoses (HME) require differentiation during diagnosis. Maffucci syndrome can be distinguished clinically by the presence of hemangiomas and lymphangiomas and genetically through R132C IDH1 hotspot mutations. [15] HME features osteochondromas which are near the surface the bone whereas enchondromas featured in Ollier disease and Maffucci are more towards the center of the bone. [3] Also, neural compressions are more commonly found in HME than in Ollier disease.

Treatment

The condition of Ollier disease cannot be treated for but the complications that arise such as fractures, growth defects, and tumors can be surgically treated. These are typically done to treat and remove any extraneous bone tissue while preserving the function of limb if possible. [11]

Fractures have been treated using a variety of methods such as bone grafting, internal fixation, corticoplasty, Ilizarov technique, elastic stable intramedullary nailing system (ESIN), and flexible intramedullary nailing (FIN).   

Corticoplasty has been shown to have success in treating hand lesions and deformities while retaining normal function. [23] [24] The surgery utilizes the removal of tissue (curettage) and bone reconstruction in order to remove enchondromas and improve cosmetic appearance. Many cases of corticoplasty have been shown improvement in appearances while maintaining function. Recurrence of enchondromas was observed in some cases. In cases of Ollier disease, early surgical treatment of enchondromas in the hand is recommended.

The Ilizarov technique is a form of noninvasive treatment that can sometimes be used to reshape and correct deformities and misaligned limb bones. [25] [26] It uses the process of external fixation through the scaffolding of pins or wires into the bone in an attempt to transform enchondromata into normal bone tissue. This method of treatment is very safe but is also very strenuous as it a long-term procedure. The ring fixators used in the Ilizarov technique have been shown to be very versatile for realigning and lengthening limb bones while also managing soft tissue tension. [27] Complications from this procedure may include a recurrence in limb lengthening complications such as premature healing requiring osteoclasis and a return of angular deformities. Reduced latency periods followed by faster distraction times are encouraged in order to prevent premature healing. The Ilizarov technique has shown to have positive outcomes for many cases of Ollier disease with some patients even experiencing full correction of deformity and length in best cases scenarios.

Elastic stable intramedullary nailing system (ESIN) and flexible intramedullary nailing (FIN) are more recent surgical procedures that utilize internal fixation that has been shown to reduce the Healing Index and minimize complications. [28] [29] Similarly to the Ilizarov technique, the procedure is intended to correct deformities and elongate limb bones. This form of treatment is not suitable for the elongation of bones with a small shaft diameter or sections containing open growth zones. Patients with severe forms of Ollier disease also are not suited for surgery because of an increased risk of complications due to bone frame instability. Both the elastic stable intramedullary nailing system (ESIN) and flexible intramedullary nailing (FIN) use two bent elastic nails in order to allow for greater realignment and stability. This technique used in conjunction with a circular external fixator has been shown to significantly reduce Healing Index values in both monosegmental and polysegmental lengthening. Another advantage is that no fractures or deformities were found in later follow ups of 2 to 5 years.

Elastic stable intramedullary nailing system (ESIN) requires a longer duration of external fixation for most procedures compared to flexible intramedullary nailing (FIN).[ citation needed ]

Malignant transformations of any or multiple enchondromas are common in patients with Ollier disease and typically emerge in young adults often requiring surgery. The average age of patients of Ollier disease for their first surgery to treat their chondrosarcoma is thirty-three. Some examples of surgical procedures performed to treat secondary malignant bone neoplasms from Ollier disease include amputation, wide-local excisions, hemipelvectomy, and arthroplasty. [30] Cobalt and chemotherapy are typically not primary methods of surgery as chondrosarcomas generally do not have enough blood supply to make it an effective form of treatment. [31] These are done to treat and remove any extraneous bone tissue while preserving the function of limb if possible. [11]

Epidemiology

One out of every 100,000 people is estimated to have Ollier disease. However, this estimate may be low due to under reporting of cases from asymptomatic or mild conditions. [17] There are many contradicting studies that report different prevalence rates between genders as one study indicates that it affects both sexes equally while other studies purporting that it affects men or women more frequently. [17] [8] [20] The average age of diagnosis is 13 years. Ollier disease is not normally diagnosed until early childhood due to lack of visible symptoms present at birth despite lesions being present using radiography. Although most research suggests that Ollier disease is spontaneous and nonhereditary, there are some cases where it appears among family members.

Eponyms

The disorder is named after French surgeon Louis Léopold Ollier. [32] Late in the 19th century, Ollier was one of the first to distinguish between enchondromatosis and this condition by highlighting the pattern of abnormal and asymmetrical enchondromas distributions in Ollier disease. [3]

See also

Related Research Articles

<span class="mw-page-title-main">Proteus syndrome</span> Human genetic disorder

Proteus syndrome is a rare disorder with a genetic background that can cause tissue overgrowth involving all three embryonic lineages. Patients with Proteus syndrome tend to have an increased risk of embryonic tumor development. The clinical and radiographic symptoms of Proteus syndrome are highly variable, as are its orthopedic manifestations.

<span class="mw-page-title-main">Osteopetrosis</span> Rare disease of the bones

Osteopetrosis, literally "stone bone", also known as marble bone disease or Albers-Schönberg disease, is an extremely rare inherited disorder whereby the bones harden, becoming denser, in contrast to more prevalent conditions like osteoporosis, in which the bones become less dense and more brittle, or osteomalacia, in which the bones soften. Osteopetrosis can cause bones to dissolve and break.

<span class="mw-page-title-main">Hereditary multiple exostoses</span> Rare skeletal disorder

Hereditary multiple osteochondromas (HMO), also known as hereditary multiple exostoses, is a disorder characterized by the development of multiple benign osteocartilaginous masses (exostoses) in relation to the ends of long bones of the lower limbs such as the femurs and tibias and of the upper limbs such as the humeri and forearm bones. They are also known as osteochondromas. Additional sites of occurrence include on flat bones such as the pelvic bone and scapula. The distribution and number of these exostoses show a wide diversity among affected individuals. Exostoses usually present during childhood. The vast majority of affected individuals become clinically manifest by the time they reach adolescence. A small percentage of affected individuals are at risk for development of sarcomas as a result of malignant transformation. The incidence of hereditary multiple exostoses is around 1 in 50,000 individuals. Hereditary multiple osteochondromas is the preferred term used by the World Health Organization.

<span class="mw-page-title-main">Chondrosarcoma</span> Medical condition

Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are chondrosarcomas. It is resistant to chemotherapy and radiotherapy. Unlike other primary bone sarcomas that mainly affect children and adolescents, a chondrosarcoma can present at any age. It more often affects the axial skeleton than the appendicular skeleton.

<span class="mw-page-title-main">Isocitrate dehydrogenase</span> Class of enzymes

Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome.

<span class="mw-page-title-main">Apert syndrome</span> Congenital disorder of the skull and digits

Apert syndrome is a form of acrocephalosyndactyly, a congenital disorder characterized by malformations of the skull, face, hands and feet. It is classified as a branchial arch syndrome, affecting the first branchial arch, the precursor of the maxilla and mandible. Disturbances in the development of the branchial arches in fetal development create lasting and widespread effects.

<span class="mw-page-title-main">Fibrous dysplasia of bone</span> Medical condition

Fibrous dysplasia is a disorder where normal bone and marrow is replaced with fibrous tissue, resulting in formation of bone that is weak and prone to expansion. As a result, most complications result from fracture, deformity, functional impairment, and pain. Disease occurs along a broad clinical spectrum ranging from asymptomatic, incidental lesions, to severe disabling disease. Disease can affect one bone (monostotic), multiple (polyostotic), or all bones (panostotic) and may occur in isolation or in combination with café au lait skin macules and hyperfunctioning endocrinopathies, termed McCune–Albright syndrome. More rarely, fibrous dysplasia may be associated with intramuscular myxomas, termed Mazabraud's syndrome. Fibrous dysplasia is very rare, and there is no known cure. Fibrous dysplasia is not a form of cancer.

<span class="mw-page-title-main">Neurofibromatosis type I</span> Type of neurofibromatosis disease

Neurofibromatosis type I (NF-1), or von Recklinghausen syndrome, is a complex multi-system human disorder caused by the mutation of Neurofibromin 1, a gene on chromosome 17 that is responsible for production of a protein (neurofibromin) which is needed for normal function in many human cell types. NF-1 causes tumors along the nervous system which can grow anywhere on the body. NF-1 is one of the most common genetic disorders and is not limited to any person's race or sex. NF-1 is an autosomal dominant disorder, which means that mutation or deletion of one copy of the NF-1 gene is sufficient for the development of NF-1, although presentation varies widely and is often different even between relatives affected by NF-1.

<span class="mw-page-title-main">Enchondroma</span> Medical condition

Enchondroma is a type of benign bone tumor belonging to the group of cartilage tumors. There may be no symptoms, or it may present typically in the short tubular bones of the hands with a swelling, pain or pathological fracture.

<span class="mw-page-title-main">Osteochondroma</span> Medical condition

Osteochondromas are the most common benign tumors of the bones. The tumors take the form of cartilage-capped bony projections or outgrowth on the surface of bones exostoses. It is characterized as a type of overgrowth that can occur in any bone where cartilage forms bone. Tumors most commonly affect long bones about the knee and in the forearm. Additionally, flat bones such as the pelvis and scapula may be affected. Hereditary multiple exostoses usually present during childhood. Yet, the vast majority of affected individuals become clinically manifest by the time they reach adolescence. Osteochondromas occur in 3% of the general population and represent 35% of all benign tumors and 8% of all bone tumors. The majority of these tumors are solitary non-hereditary lesions and approximately 15% of osteochondromas occur as hereditary multiple exostoses preferably known as hereditary multiple osteochondromas (HMOs). Osteochondromas do not result from injury and the exact cause remains unknown. Recent research has indicated that multiple osteochondromas is an autosomal dominant inherited disease. Germ line mutations in EXT1 and EXT2 genes located on chromosomes 8 and 11 have been associated with the cause of the disease. The treatment choice for osteochondroma is surgical removal of solitary lesion or partial excision of the outgrowth, when symptoms cause motion limitations or nerve and blood vessel impingements. In hereditary multiple exostoses the indications of surgery are based upon multiple factors that are taken collectively, namely: patient's age, tumor location and number, accompanying symptomatology, esthetic concerns, family history and underlying gene mutation. A variety of surgical procedures have been employed to remedy hereditary multiple exostoses such as osteochondroma excision, bone lengthening, corrective osteotomy and hemiepiphysiodesis. Sometimes a combination of the previous procedures is used. The indicators of surgical success in regard to disease and patient characteristics are greatly disputable. Because most studies of hereditary multiple exostoses are retrospective and of limited sample size with missing data, the best evidence for each of the currently practiced surgical procedures is lacking.

<span class="mw-page-title-main">Metachondromatosis</span> Medical condition

Metachondromatosis is an autosomal dominant, incompletely penetrant genetic disease affecting the growth of bones, leading to exostoses primarily in the hands and feet as well as enchondromas of long bone metaphyses and iliac crests. This syndrome affects mainly tubular bones, though it can also involve the vertebrae, small joints, and flat bones. The disease is thought to affect exon 4 of the PTPN11 gene. Metachondromatosis is believed to be caused by an 11 base pair deletion resulting in a frameshift and nonsense mutation. The disease was discovered and named in 1971 by Pierre Maroteaux, a French physician, when he observed two families with skeletal radiologic features with exostoses and Ollier disease. The observation of one family with five affected people led to the identification of the disease as autosomal dominant. There have been less than 40 cases of the disease reported to date.

<span class="mw-page-title-main">Distraction osteogenesis</span> Gradual bone lengthening

Distraction osteogenesis (DO), also called callus distraction, callotasis and osteodistraction, is a process used in orthopedic surgery, podiatric surgery, and oral and maxillofacial surgery to repair skeletal deformities and in reconstructive surgery. The procedure involves cutting and slowly separating bone, allowing the bone healing process to fill in the gap.

Phakomatoses, also known neurocutaneous syndromes, are a group of multisystemic diseases that most prominently affect structures primarily derived from the ectoderm such as the central nervous system, skin and eyes. The majority of phakomatoses are single-gene disorders that may be inherited in an autosomal dominant, autosomal recessive or X-linked pattern. Presentations may vary dramatically between patients with the same particular syndrome due to mosaicism, variable expressivity, and penetrance.

<span class="mw-page-title-main">McCune–Albright syndrome</span> Mosaic genetic disorder affecting the bone, skin and endocrine systems

McCune–Albright syndrome is a complex genetic disorder affecting the bone, skin and endocrine systems. It is a mosaic disease arising from somatic activating mutations in GNAS, which encodes the alpha-subunit of the Gs heterotrimeric G protein.

<span class="mw-page-title-main">Nail–patella syndrome</span> Medical condition

Nail–patella syndrome is a genetic disorder that results in small, poorly developed nails and kneecaps, but can also affect many other areas of the body, such as the elbows, chest, and hips. The name "nail–patella" can be very misleading because the syndrome often affects many other areas of the body, including even the production of certain proteins. The severity of these effects varies depending on the individual. It is also referred to as iliac horn syndrome, hereditary onychoosteodysplasia, Fong disease or Turner–Kieser syndrome.

Osteochondrodysplasia is a general term for a disorder of the development (dysplasia) of bone ("osteo") and cartilage ("chondro"). Osteochondrodysplasias are rare diseases. About 1 in 5,000 babies are born with some type of skeletal dysplasia. Nonetheless, if taken collectively, genetic skeletal dysplasias or osteochondrodysplasias comprise a recognizable group of genetically determined disorders with generalized skeletal affection. Osteochondrodysplasias can result in marked functional limitation and even mortality.

<span class="mw-page-title-main">Maffucci syndrome</span> Medical condition

Maffucci syndrome is a very rare disorder in which multiple benign tumors of cartilage develop within the bones. The tumors most commonly appear in the bones of the hands, feet, and limbs, causing bone deformities and short limbs.

<span class="mw-page-title-main">Angelo Maffucci</span>

Angelo Maria Maffucci was an Italian pathologist of the nineteenth century. His most important scientific contribution is related to the description of the disease known as Maffucci's Syndrome. Maffucci was a pioneer in the field of embryonal infective pathology. His settlement in Pisa, as the chairman of Pathology, represents a very significant moment for the Pisan academic environment and for the University of Pisa.

<span class="mw-page-title-main">IDH2</span>

Isocitrate dehydrogenase [NADP], mitochondrial is an enzyme that in humans is encoded by the IDH2 gene.

<span class="mw-page-title-main">Index of trauma and orthopaedics articles</span>

Orthopedic surgery is the branch of surgery concerned with conditions involving the musculoskeletal system. Orthopedic surgeons use both surgical and nonsurgical means to treat musculoskeletal injuries, sports injuries, degenerative diseases, infections, bone tumours, and congenital limb deformities. Trauma surgery and traumatology is a sub-specialty dealing with the operative management of fractures, major trauma and the multiply-injured patient.

References

  1. 1 2 3 4 5 Muthusamy, Saravanaraja; Conway, Sheila A.; Temple, H. Thomas (July 2014). "Five Polyostotic Conditions That General Orthopedic Surgeons Should Recognize (or Should Not Miss)". Orthopedic Clinics of North America. 45 (3): 417–429. doi:10.1016/j.ocl.2014.04.004. ISSN   0030-5898. PMID   24975767.
  2. 1 2 Verdegaal, Suzan H.M.; Bovée, Judith V.M.G.; Pansuriya, Twinkal C.; Grimer, Robert J.; Ozger, Harzem; Jutte, Paul C.; San Julian, Mikel; Biau, David J.; van der Geest, Ingrid C.M.; Leithner, Andreas; Streitbürger, Arne (December 2011). "Incidence, Predictive Factors, and Prognosis of Chondrosarcoma in Patients with Ollier Disease and Maffucci Syndrome: An International Multicenter Study of 161 Patients". The Oncologist. 16 (12): 1771–1779. doi:10.1634/theoncologist.2011-0200. ISSN   1083-7159. PMC   3248776 . PMID   22147000.
  3. 1 2 3 4 5 Silve C, Jüppner H (2006). "Ollier disease". Orphanet J Rare Dis. 1: 37. doi: 10.1186/1750-1172-1-37 . PMC   1592482 . PMID   16995932.
  4. ↑ Turek's orthopaedics principles and their application (6th ed.). Philadelphia: Lippincott Williams & Wilkins. 2005. p. 438. ISBN   9780781742986.
  5. ↑ Beckingsale, Thomas B.; Shaw, Colin (June 2015). "(v) Epidemiology of bone & soft tissue sarcomas". Orthopaedics and Trauma. 29 (3): 182–188. doi:10.1016/j.mporth.2015.03.001. ISSN   1877-1327.
  6. ↑ Bready, Devin; Placantonakis, Dimitris G. (January 2019). "Molecular Pathogenesis of Low-Grade Glioma". Neurosurgery Clinics of North America. 30 (1): 17–25. doi: 10.1016/j.nec.2018.08.011 . ISSN   1042-3680. PMC   6260953 . PMID   30470401.
  7. ↑ Pearce, P.; Robertson, T.; Ortiz-Gomez, J.D.; Rajah, T.; Tollesson, G. (March 2012). "Multifocal supratentorial diffuse glioma in a young patient with Ollier disease". Journal of Clinical Neuroscience. 19 (3): 477–478. doi:10.1016/j.jocn.2011.06.019. ISSN   0967-5868. PMID   22249016. S2CID   5085163.
  8. 1 2 Ding, Chang; Chen, Wei; Liu, Fujun; Xiong, Moli; Chen, Jing (July 2019). "Skull Base Chondrosarcoma Caused by Ollier Disease: A Case Report and Literature Review". World Neurosurgery. 127: 103–108. doi:10.1016/j.wneu.2019.03.037. ISSN   1878-8750. PMID   30872199. S2CID   78091968.
  9. ↑ Stephen C. Rubin (2001). Ovarian cancer (2nd ed.). Philadelphia [u.a.]: Lippincott Williams and Wilkins. ISBN   9780781724081.
  10. ↑ Gell, J.S.; Stannard, M.W.; Ramnani, D.M.; Bradshaw, K.D. (August 1998). "Juvenile Granulosa Cell Tumor in a 13-Year-Old Girl With Enchondromatosis (Oilier's Disease): A Case Report". Journal of Pediatric and Adolescent Gynecology. 11 (3): 147–150. doi:10.1016/s1083-3188(98)70135-4. ISSN   1083-3188. PMID   9704306.
  11. 1 2 3 Lovell and Winter's pediatric orthopaedics (3rd ed.). Philadelphia: Lippincott. 1990. ISBN   9780397509140.
  12. ↑ Fang, Sean; Dimond, Donna; Amirfeyz, Rouin; Gargan, Martin (2009-08-01). "Ollier's disease and Maffucci syndrome". Orthopaedics and Trauma. 23 (4): 278–280. doi:10.1016/j.mporth.2009.01.007. ISSN   1877-1327.
  13. ↑ Bovée, Judith V. M. G.; van Roggen, J. Frans Graadt; Cleton-Jansen, Anne Marie; Taminiau, Anthony H. M.; van der Woude, Henk-Jan; Hogendoorn, Pancras C. W. (2000-10-01). "Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study". Human Pathology. 31 (10): 1299–1303. doi:10.1053/hupa.2000.19308. ISSN   0046-8177. PMID   11070122.
  14. ↑ Liu, Jue; Hudkins, Philip G.; Swee, Ronald G.; Unni, Krishnan K. (1987). "Bone sarcomas associated with ollier's disease". Cancer. 59 (7): 1376–1385. doi: 10.1002/1097-0142(19870401)59:7<1376::aid-cncr2820590725>3.0.co;2-f . ISSN   1097-0142. PMID   3815310.
  15. 1 2 3 Kurek, Kyle C.; Pansuriya, Twinkal C.; van Ruler, Maayke A.J.H.; van den Akker, Brendy; Luks, Valerie L.; Verbeke, Sofie L.J.; Kozakewich, Harry P.; Sciot, Raf; Lev, Dina; Lazar, Alexander J.; Fletcher, Christopher D.M. (May 2013). "R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations". The American Journal of Pathology. 182 (5): 1494–1500. doi: 10.1016/j.ajpath.2013.01.012 . ISSN   0002-9440. PMID   23485734.
  16. ↑ Noël, Georges; Feuvret, Loïc; Calugaru, Valentin; Hadadi, Khalid; Baillet, François; Mazeron, Jean-jacques; Habrand, Jean-louis (December 2004). "Chondrosarcomas of the base of the skull in Ollier's disease or Maffucci's syndrome Three Case Reports and Review of the Literature". Acta Oncologica. 43 (8): 705–710. doi: 10.1080/02841860410002770 . ISSN   0284-186X. PMID   15764214.
  17. 1 2 3 4 Pansuriya, Twinkal C; Kroon, Herman M; Bovée, Judith VMG (2010-06-26). "Enchondromatosis: insights on the different subtypes". International Journal of Clinical and Experimental Pathology. 3 (6): 557–569. ISSN   1936-2625. PMC   2907117 . PMID   20661403.
  18. ↑ Silve, Caroline; Jüppner, Harald (2018-01-01), Thakker, Rajesh V.; Whyte, Michael P.; Eisman, John A.; Igarashi, Takashi (eds.), "Chapter 36 - Genetic Disorders Caused by Mutations in the PTH/PTHrP Receptor, its Ligands, and Downstream Effector Molecules", Genetics of Bone Biology and Skeletal Disease (Second Edition), Academic Press, pp. 655–674, ISBN   978-0-12-804182-6 , retrieved 2020-05-03
  19. 1 2 Pansuriya, Twinkal C; van Eijk, Ronald; d'Adamo, Pio; van Ruler, Maayke A J H; Kuijjer, Marieke L; Oosting, Jan; Cleton-Jansen, Anne-Marie; van Oosterwijk, Jolieke G; Verbeke, Sofie L J; Meijer, Daniëlle; van Wezel, Tom (2011-11-06). "Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome". Nature Genetics. 43 (12): 1256–1261. doi:10.1038/ng.1004. ISSN   1061-4036. PMC   3427908 . PMID   22057234.
  20. 1 2 Silve, Caroline; Jüppner, Harald (2006-09-22). "Ollier disease". Orphanet Journal of Rare Diseases. 1: 37. doi: 10.1186/1750-1172-1-37 . ISSN   1750-1172. PMC   1592482 . PMID   16995932.
  21. ↑ Halal, Fahed; Azouz, E. Michel (1991-03-15). "Generalized enchondromatosis in a boy with only platyspondyly in the father". American Journal of Medical Genetics. 38 (4): 588–592. doi:10.1002/ajmg.1320380418. ISSN   0148-7299. PMID   2063903.
  22. ↑ Hopyan, Sevan; Gokgoz, Nalan; Poon, Raymond; Gensure, Robert C.; Yu, Chunying; Cole, William G.; Bell, Robert S.; Jüppner, Harald; Andrulis, Irene L.; Wunder, Jay S.; Alman, Benjamin A. (2002-02-19). "A mutant PTH/PTHrP type I receptor in enchondromatosis". Nature Genetics. 30 (3): 306–310. doi:10.1038/ng844. ISSN   1061-4036. PMID   11850620. S2CID   5961561.
  23. ↑ Kim, Eugene; Miyake, Junichi; Kataoka, Toshiyuki; Oka, Kunihiro; Moritomo, Hisao; Murase, Tsuyoshi (November 2012). "Corticoplasty for Improved Appearance of Hands With Ollier Disease". The Journal of Hand Surgery. 37 (11): 2294–2299. doi:10.1016/j.jhsa.2012.08.006. ISSN   0363-5023. PMID   23040642.
  24. ↑ Klein, Céline; Delcourt, Tiphanie; Salon, Arielle; Finidori, Georges; Glorion, Christophe; Pannier, Stéphanie (October 2018). "Surgical Treatment of Enchondromas of the Hand During Childhood in Ollier Disease". The Journal of Hand Surgery. 43 (10): 946.e1–946.e5. doi: 10.1016/j.jhsa.2018.02.010 . ISSN   0363-5023. PMID   29551344.
  25. ↑ Van Loon, Pieter; Lammens, Johan (March 2008). "Malformation of the humerus in a patient with Ollier disease treated with the Ilizarov technique". Journal of Shoulder and Elbow Surgery. 17 (2): e9–e11. doi:10.1016/j.jse.2007.04.006. ISSN   1058-2746. PMID   18036843.
  26. ↑ Watanabe, Koji; Tsuchiya, Hiroyuki; Sakurakichi, Keisuke; Yamashiro, Teruhisa; Matsubara, Hidenori; Tomita, Katsuro (September 2007). "Treatment of lower limb deformities and limb-length discrepancies with the external fixator in Ollier's disease". Journal of Orthopaedic Science. 12 (5): 471–475. doi:10.1007/s00776-007-1163-9. ISSN   0949-2658. PMID   17909933. S2CID   25701102.
  27. ↑ Saleh, M.; Fernandes, J. A.; Bell, M. J.; Madan, S. S.; Robinson, K.; Kasliwal, P. D. (2015-04-30). "Limb reconstruction in Ollier\'s disease". Strategies in Trauma and Limb Reconstruction. 10 (1): 49–54. doi:10.1007/s11751-015-0223-5. ISSN   1828-8936. PMC   4395566 . PMID   25861039.
  28. ↑ Popkov, D.; Journeau, P.; Popkov, A.; Haumont, T.; Lascombes, P. (June 2010). "Ollier's disease limb lenghtening[sic]: Should intramedullary nailing be combined with circular external fixation?". Orthopaedics & Traumatology: Surgery & Research. 96 (4): 348–353. doi: 10.1016/j.otsr.2010.01.002 . ISSN   1877-0568. PMID   20472523.
  29. ↑ Popkov, Arnold; Dučić, Siniša; Lazović, Mikan; Lascombes, Pierre; Popkov, Dmitry (June 2019). "Limb lengthening and deformity correction in children with abnormal bone". Injury. 50: S79–S86. doi:10.1016/j.injury.2019.03.045. ISSN   0020-1383. PMID   30987742. S2CID   116863158.
  30. ↑ Spranger, Jürgen W.; Brill, Paula W.; Nishimura, Gen; Superti-Furga, Andrea; Unger, Sheila (September 2012), "Enchondromatosis (Ollier Disease) (MIM 166000)", Bone Dysplasias, Oxford University Press, pp. 681–684, doi:10.1093/med/9780195396089.003.0149, ISBN   978-0-19-539608-9
  31. ↑ Fang, Sean; Dimond, Donna; Amirfeyz, Rouin; Gargan, Martin (August 2009). "Ollier's disease and Maffucci syndrome". Orthopaedics and Trauma. 23 (4): 278–280. doi:10.1016/j.mporth.2009.01.007. ISSN   1877-1327.
  32. ↑ synd/1813 at Who Named It?
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.